Angina

PCI guided by quantitative flow ratio, a novel approach to estimate fractional flow reserve, was associated with lower rates of MACE at 1 year compared with PCI guided by angiography, according to results of the FAVOR III China trial.

Among patients undergoing CABG, the no-touch technique for vein harvesting reduced risk for vein graft occlusion and improved patient prognosis compared with the conventional harvesting technique, according to new research in Circulation.

Most patients with stable CAD and anginal symptoms experienced improvement in angina over time without any changes to antianginal therapy or need for coronary revascularization, according to results from the CLARIFY registry.

Microvascular angina is a significant health problem that confers risk for major adverse CV events, according to registry data from the Coronary Vasomotor Disorders International Study, or COVADIS, Group.

Among stable outpatients with CAD, 21.2% reported experiencing angina at least once monthly, researchers reported.

The FDA’s Circulatory System Devices Panel recommended the agency not approve an implantable device to treat refractory angina, saying more data are needed.

In patients who underwent PCI, trimetazidine, a drug to improve myocardial metabolism, did not improve angina recurrence or other CV outcomes, according to results of the ATPCI trial presented at the European Society of Cardiology Congress.

Despite the greater risk for mortality, elective PCI for veterans with stable angina performed at community care centers rather than integrated Veterans Affairs health care centers increased from 2015 to 2018, researchers reported.

Inferior frontal lobe activation caused in addition to mental stress was independently linked to angina at baseline and during 2-year follow-up, researchers found.

Alirocumab reduced the relative risk for major adverse CV events in patients after ACS regardless of background statin treatment, researchers found in the ODYSSEY OUTCOMES trial.